Continuous Non-Invasive Blood Pressure System Data Collection in Comparison to Invasive Radial Arterial Pressure

Sponsor
Sensifree Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT04456179
Collaborator
(none)
6
1
3
60.9

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate methods to modify blood pressure in humans and measure the effectiveness of such methods. A secondary outcome is to evaluate the performance of an investigational continuous non-invasive blood pressure (cNIBP) device created by Sensifree. The tests will per performed in non-hospitalized subjects under varied controlled conditions that include resting blood pressure and non-pharmacologically induced blood pressure changes.

Condition or Disease Intervention/Treatment Phase
  • Device: GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor
  • Device: Arrow® arterial catheterization kit (Teleflex)
N/A

Detailed Description

On a first visit a screening procedure to verify inclusion / exclusion criteria are met will be conducted. On the primary procedure visit, data collection will begin with the subjects having the investigational device, ECG sensors, and 1 or more pulse oximetry sensors placed on them for data collection and to monitor their safety for the duration of the study. A physician will place an arterial line in the radial artery. The Sensifree cNIBP system will be calibrated with an oscillometric and/or auscultatory blood pressure cuff measurement taken on the arm opposite the arterial line.

A series of blood pressure changes will be induced, including various combinations of methods.

Study Design

Study Type:
Interventional
Actual Enrollment :
6 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Evaluation of Sensifree's PPG Based Continuous & Non-Invasive Blood Pressure Monitoring System in Comparison to Invasive Radial Arterial Line
Actual Study Start Date :
Feb 3, 2020
Actual Primary Completion Date :
Feb 6, 2020
Actual Study Completion Date :
Feb 6, 2020

Outcome Measures

Primary Outcome Measures

  1. Evaluation of the magnitude of blood pressure change (measured in mmHg) cause by different isometric efforts in humans [3-4 hours per subject]

    Measure the effect of a combination of the following isometric efforts on a subject's blood pressure (measured in mmHg): Hand grip Weight lifting Leg static effort

Secondary Outcome Measures

  1. Measure the accuracy of an investigational continuous non-invasive blood pressure (cNIBP) device [3-4 hours per subject]

    Comparison of BP values (Systolic, Diastolic, MAP) that are calculated by the investigational device to the BP values measured by the arterial line during isometric effort comprising a combination of the following isometric efforts on a subject's blood pressure: Hand grip Weight lifting Leg static effort

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subject must have the ability to understand and provide written informed consent

  • Subject must be willing and able to comply with study procedures and duration

Exclusion Criteria:
  • Subject with a BMI over 39

  • Deformities or abnormalities that may prevent proper application of the device under test

  • Lateral difference in blood pressure greater than 5mmHg diastolic and 9mmHg systolic

  • Tachycardia or resting heart rate less than 45 bpm

  • Females who are pregnant, who are trying to get pregnant, (confirmed by positive urine pregnancy test unless the subject is known to be not of child-bearing potential)

  • Subjects with known respiratory conditions such as: (self-reported)

  • uncontrolled / severe asthma,

  • flu,

  • pneumonia / bronchitis,

  • shortness of breath / respiratory distress,

  • respiratory or lung surgery,

  • emphysema, COPD, lung disease

  • Subjects with known heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)

  • have had cardiovascular surgery

  • have cardiac pacemakers and/or automatic internal cardio-defibrillator

  • Chest pain (angina)

  • Abnormal pulse pressure

  • previous heart attack

  • blocked artery

  • unexplained shortness of breath

  • congestive heart failure (CHF)

  • history of stroke

  • transient ischemic attack

  • carotid artery disease

  • myocardial ischemia

  • myocardial infarction

  • cardiomyopathy

  • Pulsus Paradoxus

  • Self-reported health conditions as identified in the Health Assessment Form (self-reported)

  • diabetes,

  • uncontrolled thyroid disease,

  • kidney disease / chronic renal impairment,

  • history of seizures (except childhood febrile seizures),

  • epilepsy,

  • history of unexplained syncope,

  • recent history of frequent migraine headaches,

  • recent head injury

  • cancer / chemotherapy

  • Subjects with known clotting disorders (self-reported)

  • history of bleeding disorders or personal history of prolonged bleeding from injury

  • history of blood clots

  • hemophilia

  • current use of blood thinner: prescription or daily use of aspirin

  • Subjects with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported)

  • Subjects with a contact allergy to ultrasound gel.

  • Subjects with prior or known allergies to iodine or lidocaine (or similar pharmacological agents, e.g. Novocaine)

  • Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test

  • Subject is intoxicated during the time of the visit, or was intoxicated within 24 hours prior to study visit, as reported by the subject, or per study staff judgment.

  • Other known health condition, should be considered upon disclosure in health assessment form

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinimark Lab Louisville Colorado United States 80027

Sponsors and Collaborators

  • Sensifree Ltd.

Investigators

  • Principal Investigator: Arthur Ruiz Cabrera, M.D,

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sensifree Ltd.
ClinicalTrials.gov Identifier:
NCT04456179
Other Study ID Numbers:
  • PR2020-363
First Posted:
Jul 2, 2020
Last Update Posted:
Jul 2, 2020
Last Verified:
Jun 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes

Study Results

No Results Posted as of Jul 2, 2020